Takayuki Yoshimoto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3758689/publications.pdf

Version: 2024-02-01

68 papers 3,962 citations

34 h-index 62 g-index

70 all docs

70 docs citations

times ranked

70

4856 citing authors

#	Article	IF	CITATIONS
1	Potent Antitumor Activity of Interleukin-27. Cancer Research, 2004, 64, 1152-1156.	0.9	225
2	An Indispensable Role for STAT1 in IL-27-Induced T-bet Expression but Not Proliferation of Naive CD4+ T Cells. Journal of Immunology, 2004, 173, 3871-3877.	0.8	196
3	IL-27 Suppresses Th2 Cell Development and Th2 Cytokines Production from Polarized Th2 Cells: A Novel Therapeutic Way for Th2-Mediated Allergic Inflammation. Journal of Immunology, 2007, 179, 4415-4423.	0.8	180
4	A Role for IL-27 in Early Regulation of Th1 Differentiation. Journal of Immunology, 2005, 175, 2191-2200.	0.8	170
5	Augmentation of Effector CD8+ T Cell Generation with Enhanced Granzyme B Expression by IL-27. Journal of Immunology, 2005, 175, 1686-1693.	0.8	162
6	Antiangiogenic and Antitumor Activities of IL-27. Journal of Immunology, 2006, 176, 7317-7324.	0.8	161
7	Notch signaling drives IL-22 secretion in CD4 ⁺ T cells by stimulating the aryl hydrocarbon receptor. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 5943-5948.	7.1	147
8	Regulation of Antitumor Immune Responses by the IL-12 Family Cytokines, IL-12, IL-23, and IL-27. Clinical and Developmental Immunology, 2010, 2010, 1-9.	3.3	144
9	Interleukin-23 and Interleukin-27 Exert Quite Different Antitumor and Vaccine Effects on Poorly Immunogenic Melanoma. Cancer Research, 2006, 66, 6395-6404.	0.9	135
10	IL-27 Suppresses CD28-Medicated IL-2 Production through Suppressor of Cytokine Signaling 3. Journal of Immunology, 2006, 176, 2773-2780.	0.8	132
11	Pivotal Roles of T-Helper 17-Related Cytokines, IL-17, IL-22, and IL-23, in Inflammatory Diseases. Clinical and Developmental Immunology, 2013, 2013, 1-13.	3.3	132
12	Induction of IgG2a Class Switching in B Cells by IL-27. Journal of Immunology, 2004, 173, 2479-2485.	0.8	125
13	Antiproliferative Activity of IL-27 on Melanoma. Journal of Immunology, 2008, 180, 6527-6535.	0.8	122
14	Expanding Diversity in Molecular Structures and Functions of the IL-6/IL-12 Heterodimeric Cytokine Family. Frontiers in Immunology, 2016, 7, 479.	4.8	107
15	IL-27 Induces Th1 Differentiation via p38 MAPK/T-bet- and Intercellular Adhesion Molecule-1/LFA-1/ERK1/2-Dependent Pathways. Journal of Immunology, 2006, 177, 7579-7587.	0.8	106
16	Interleukin-27 Activates Natural Killer Cells and Suppresses NK-Resistant Head and Neck Squamous Cell Carcinoma through Inducing Antibody-Dependent Cellular Cytotoxicity. Cancer Research, 2009, 69, 2523-2530.	0.9	95
17	Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: inhibitory effects on osteoclast differentiation. Journal of Bone and Mineral Metabolism, 2007, 25, 277-285.	2.7	80
18	Interleukin-27 directly induces differentiation in hematopoietic stem cells. Blood, 2008, 111, 1903-1912.	1.4	78

#	Article	IF	CITATIONS
19	Adjuvant Activities of Novel Cytokines, Interleukin-23 (IL-23) and IL-27, for Induction of Hepatitis C Virus-Specific Cytotoxic T Lymphocytes in HLA-A*0201 Transgenic Mice. Journal of Virology, 2004, 78, 9093-9104.	3.4	76
20	Gamma Interferon Production Is Critical for Protective Immunity to Infection with Blood-Stage <i>Plasmodium berghei </i> XAT but Neither NO Production nor NK Cell Activation Is Critical. Infection and Immunity, 1999, 67, 2349-2356.	2.2	76
21	Local expression of interleukinâ€27 ameliorates collagenâ€induced arthritis. Arthritis and Rheumatism, 2011, 63, 2289-2298.	6.7	74
22	STAT3 Is Indispensable to IL-27-Mediated Cell Proliferation but Not to IL-27-Induced Th1 Differentiation and Suppression of Proinflammatory Cytokine Production. Journal of Immunology, 2008, 180, 2903-2911.	0.8	68
23	TGF- \hat{l}^2 is necessary for induction of IL-23R and Th17 differentiation by IL-6 and IL-23. Biochemical and Biophysical Research Communications, 2009, 386, 105-110.	2.1	68
24	Regulation of myelopoiesis by proinflammatory cytokines in infectious diseases. Cellular and Molecular Life Sciences, 2018, 75, 1363-1376.	5.4	68
25	Positive Modulation of IL-12 Signaling by Sphingosine Kinase 2 Associating with the IL-12 Receptor \hat{l}^21 Cytoplasmic Region. Journal of Immunology, 2003, 171, 1352-1359.	0.8	66
26	A Critical Role of Fc Receptor-Mediated Antibody-Dependent Phagocytosis in the Host Resistance to Blood-Stage <i>Plasmodium berghei</i> XAT Infection. Journal of Immunology, 2001, 166, 6236-6241.	0.8	64
27	Promotion of Expansion and Differentiation of Hematopoietic Stem Cells by Interleukin-27 into Myeloid Progenitors to Control Infection in Emergency Myelopoiesis. PLoS Pathogens, 2016, 12, e1005507.	4.7	60
28	No inhibition of IL-27 signaling by soluble gp130. Biochemical and Biophysical Research Communications, 2005, 326, 724-728.	2.1	58
29	Alternatively activated macrophages express the IL-27 receptor alpha chain WSX-1. Immunobiology, 2006, 211, 427-436.	1.9	58
30	A Pivotal Role for Interleukin-27 in CD8 ⁺ T Cell Functions and Generation of Cytotoxic T Lymphocytes. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-10.	3.0	51
31	IL-23 Enhances Host Defense against Vaccinia Virus Infection Via a Mechanism Partly Involving IL-17. Journal of Immunology, 2007, 179, 3917-3925.	0.8	50
32	Potential clinical application of interleukinâ€27 as an antitumor agent. Cancer Science, 2015, 106, 1103-1110.	3.9	49
33	Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma. Molecular Immunology, 2009, 46, 1654-1662.	2.2	47
34	Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib. Cancer Science, 2013, 104, 1146-1153.	3.9	37
35	Regulation of the development of acute hepatitis by ILâ€23 through ILâ€22 and ILâ€17 production. European Journal of Immunology, 2011, 41, 2828-2839.	2.9	36
36	Interleukinâ€12â€Dependent Mechanisms in the Clearance of Bloodâ€Stage Murine Malaria Parasite <i>Plasmodium berghei</i> XAT, an Attenuated Variant of <i>P. berghei</i> NK65. Journal of Infectious Diseases, 1998, 177, 1674-1681.	4.0	30

3

#	Article	IF	CITATIONS
37	IL-27 promotes nitric oxide production induced by LPS through STAT1, NF-κB and MAPKs. Immunobiology, 2013, 218, 628-634.	1.9	30
38	IL-27 Enhances the Expression of TRAIL and TLR3 in Human Melanomas and Inhibits Their Tumor Growth in Cooperation with a TLR3 Agonist Poly(I:C) Partly in a TRAIL-Dependent Manner. PLoS ONE, 2013, 8, e76159.	2.5	29
39	<scp>IL</scp> â€17Aâ€producing <scp>CD</scp> 30 ⁺ Vδ1 T cells drive inflammationâ€induced can progression. Cancer Science, 2016, 107, 1206-1214.	cer 3.9	28
40	Integrin αvβ3 enhances the suppressive effect of interferonâ€Ĵ³ on hematopoietic stem cells. EMBO Journal, 2017, 36, 2390-2403.	7.8	28
41	Plasmacytoid dendritic cells protect against immune-mediated acute liver injury via IL-35. Journal of Clinical Investigation, 2019, 129, 3201-3213.	8.2	27
42	Interleukins and cancer immunotherapy. Immunotherapy, 2009, 1, 825-844.	2.0	26
43	Interleukin-27 Exerts Its Antitumor Effects by Promoting Differentiation of Hematopoietic Stem Cells to M1 Macrophages. Cancer Research, 2018, 78, 182-194.	0.9	25
44	Contribution of IL-12/IL-35 Common Subunit p35 to Maintaining the Testicular Immune Privilege. PLoS ONE, 2014, 9, e96120.	2.5	24
45	Interleukin (IL)-18, cooperatively with IL-23, induces prominent inflammation and enhances psoriasis-like epidermal hyperplasia. Archives of Dermatological Research, 2017, 309, 315-321.	1.9	24
46	Necroptosis of Intestinal Epithelial Cells Induces Type 3 Innate Lymphoid Cell-Dependent Lethal Ileitis. IScience, 2019, 15, 536-551.	4.1	21
47	Prediction of Chemical Respiratory and Contact Sensitizers by OX40L Expression in Dendritic Cells Using a Novel 3D Coculture System. Frontiers in Immunology, 2017, 8, 929.	4.8	19
48	Antitumor Activities of Interleukin-27 on Melanoma. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2010, 10, 41-46.	1.2	18
49	Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely. Drug Design, Development and Therapy, 2014, 8, 1151.	4.3	17
50	Interleukin- $1\hat{l}^2$ in peripheral monocytes is associated with seizure frequency in pediatric drug-resistant epilepsy. Journal of Neuroimmunology, 2021, 352, 577475.	2.3	15
51	Antimelanoma immunotherapy: clinical and preclinical applications of IL-12 family members. Immunotherapy, 2010, 2, 697-709.	2.0	14
52	Vaccination with OVA-bound nanoparticles encapsulating IL-7 inhibits the growth of OVA-expressing E.G7 tumor cells in vivo. Oncology Reports, 2015, 33, 292-296.	2.6	13
53	Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse. Oncolmmunology, 2014, 3, e28861.	4.6	11
54	Intratumoral CD4+ T Lymphodepletion Sensitizes Poorly Immunogenic Melanomas to Immunotherapy with an OX40 Agonist. Journal of Investigative Dermatology, 2014, 134, 1884-1892.	0.7	11

#	Article	IF	CITATIONS
55	Microbial Antigen-Presenting Extracellular Vesicles Derived from Genetically Modified Tumor Cells Promote Antitumor Activity of Dendritic Cells. Pharmaceutics, 2021, 13, 57.	4.5	9
56	IL-23p19 and CD5 antigen-like form a possible novel heterodimeric cytokine and contribute to experimental autoimmune encephalomyelitis development. Scientific Reports, 2021, 11, 5266.	3.3	8
57	Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report. Journal of Medical Case Reports, 2021, 15, 403.	0.8	5
58	A Chaperone-Like Role for EBI3 in Collaboration With Calnexin Under Inflammatory Conditions. Frontiers in Immunology, 2021, 12, 757669.	4.8	5
59	EBV-induced gene 3 augments IL-23R \hat{l} ± protein expression through a chaperone calnexin. Journal of Clinical Investigation, 2020, 130, 6124-6140.	8.2	5
60	Rap1 prevents colitogenic Th17 cell expansion and facilitates Treg cell differentiation and distal TCR signaling. Communications Biology, 2022, 5, 206.	4.4	5
61	Therapeutic potential of interleukin-27 against cancers in preclinical mouse models. Oncolmmunology, 2015, 4, e1042200.	4.6	4
62	Changes in Expression of Specific mRNA Transcripts after Single- or Re-Irradiation in Mouse Testes. Genes, 2022, 13, 151.	2.4	3
63	Protective effects against tumors and infection by interleukin-27 through promotion of expansion and differentiation of hematopoietic stem cells into myeloid progenitors. Oncolmmunology, 2018, 7, e1421892.	4.6	2
64	Activation Levels of Natural Killer Cells and CD8+ T Cells Correlate Highly with Sustained Complete Molecular Response After Discontinuation of Imatinib in Chronic Myeloid Leukemia Patients. Blood, 2012, 120, 3745-3745.	1.4	1
65	Adding collagen to adipose tissue transplant increases engraftment by promoting cell proliferation, neovascularisation and macrophage activity in a rat model. International Wound Journal, 2021, , .	2.9	1
66	A novel coculture system for assessing respiratory sensitizing potential by IL-4 in T cells. ALTEX: Alternatives To Animal Experimentation, 2022, , .	1.5	1
67	CD40 Ligand Rescues Inhibitor of Differentiation 3-Mediated G1Arrest Induced by Anti-IgM in WEHI-231 B Lymphoma Cells. Journal of the Royal Society of Medicine, 1923, 16, 2453-2461.	0.1	0
68	Interleukin-27: Regulation of Immune Responses and Disease Development by a Pleiotropic Cytokine with Pro- and Anti-inflammatory Properties., 2014,, 353-375.		0